Ann: Results of Meeting, page-78

Hmmm - if you are right then God help the next director who stands for re-election. I do see that there may be some predators around who are not happy about the partnerships that are forming. It would likely be creating a hurdle for somebody looking for a complete buyout. Going down the path of licensing makes a buyout more complicated if it arises from a competing Big Pharma. Why would they be wanting to partner with other BP or research bodies when they want the whole of the pie for themselves? Many scenarios can be surmised - just adding some thoughts to and an extension to your theory @Oddoneout